NASDAQ:LPTX - Leap Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.87 -0.10 (-1.43 %)
(As of 09/20/2018 04:00 PM ET)
Previous Close$6.97
Today's Range$6.80 - $7.07
52-Week Range$4.90 - $10.25
Volume36,735 shs
Average Volume43,975 shs
Market Capitalization$98.50 million
P/E Ratio-2.08
Dividend YieldN/A
Beta-0.26
Leap Therapeutics logoLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. Its clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360

Debt

Debt-to-Equity RatioN/A
Current Ratio5.32
Quick Ratio5.32

Price-To-Earnings

Trailing P/E Ratio-2.08
Forward P/E Ratio-3.15
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book7.63

Profitability

EPS (Most Recent Fiscal Year)($3.31)
Net Income$-29,720,000.00
Net MarginsN/A
Return on Equity-203.23%
Return on Assets-86.48%

Miscellaneous

Employees22
Outstanding Shares14,700,000
Market Cap$98.50 million

Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics Inc (NASDAQ:LPTX) posted its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.01. View Leap Therapeutics' Earnings History.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Leap Therapeutics.

What price target have analysts set for LPTX?

1 brokerages have issued 12 month price objectives for Leap Therapeutics' stock. Their predictions range from $12.50 to $12.50. On average, they expect Leap Therapeutics' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.

What is the consensus analysts' recommendation for Leap Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.

What are Wall Street analysts saying about Leap Therapeutics stock?

Here are some recent quotes from research analysts about Leap Therapeutics stock:
  • 1. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (8/22/2018)
  • 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018)

Who are some of Leap Therapeutics' key competitors?

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the folowing people:
  • Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 64)
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 49)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 62)
  • Dr. Cynthia A. Sirard, VP of Clinical Devel.

Has Leap Therapeutics been receiving favorable news coverage?

News stories about LPTX stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Leap Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also gave news stories about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Leap Therapeutics.

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include DAFNA Capital Management LLC (1.05%), Renaissance Technologies LLC (0.78%), Point72 Asset Management L.P. (0.52%), DRW Securities LLC (0.27%) and Creative Planning (0.11%). View Institutional Ownership Trends for Leap Therapeutics.

Which institutional investors are selling Leap Therapeutics stock?

LPTX stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC. View Insider Buying and Selling for Leap Therapeutics.

Which institutional investors are buying Leap Therapeutics stock?

LPTX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., DRW Securities LLC, Renaissance Technologies LLC and Creative Planning. View Insider Buying and Selling for Leap Therapeutics.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $6.87.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $98.50 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.


MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel